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IGF-IR Promotes Prostate Cancer Growth by Stabilizing
a5b1 Integrin Protein Levels
Aejaz Sayeed, Carmine Fedele, Marco Trerotola¤, Kirat K. Ganguly, Lucia R. Languino*
Department of Cancer Biology, Prostate Cancer Discovery and Development Program, Thomas Jefferson University, Philadelphia, Pennsylvania, United States of America

Abstract
Dynamic crosstalk between growth factor receptors, cell adhesion molecules and extracellular matrix is essential for cancer
cell migration and invasion. Integrins are transmembrane receptors that bind extracellular matrix proteins and enable cell
adhesion and cytoskeletal organization. They also mediate signal transduction to regulate cell proliferation and survival. The
type 1 insulin-like growth factor receptor (IGF-IR) mediates tumor cell growth, adhesion and inhibition of apoptosis in
several types of cancer. We have previously demonstrated that b1 integrins regulate anchorage-independent growth of
prostate cancer (PrCa) cells by regulating IGF-IR expression and androgen receptor-mediated transcriptional functions.
Furthermore, we have recently reported that IGF-IR regulates the expression of b1 integrins in PrCa cells. We have dissected
the mechanism through which IGF-IR regulates b1 integrin expression in PrCa. Here we report that IGF-IR is crucial for PrCa
cell growth and that b1 integrins contribute to the regulation of proliferation by IGF-IR. We demonstrate that b1 integrin
regulation by IGF-IR does not occur at the mRNA level. Exogenous expression of a CD4 - b1 integrin cytoplasmic domain
chimera does not interfere with such regulation and fails to stabilize b1 integrin expression in the absence of IGF-IR. This
appears to be due to the lack of interaction between the b1 cytoplasmic domain and IGF-IR. We demonstrate that IGF-IR
stabilizes the b1 subunit by protecting it from proteasomal degradation. The a5 subunit, one of the binding partners of b1, is
also downregulated along with b1 upon IGF-IR knockdown while no change is observed in the expression of the a2, a3, a4, a6
and a7 subunits. Our results reveal a crucial mechanistic role for the a5b1 integrin, downstream of IGF-IR, in regulating
cancer growth.
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sites of integrin-mediated signaling [9] and consequently modulate
integrin-mediated cell adhesion and motility. Physical and
functional interactions between integrins and components of
growth factor signaling pathways, including insulin-like growth
factor 1 (IGF-1) or its downstream signaling proteins [10,11], have
been reported. Our laboratory has demonstrated that b1 integrins
selectively modulate type 1 insulin-like growth factor receptor
(IGF-IR)-mediated signaling and functions in PrCa [10,12]. IGF-1
has also been reported to induce adhesion and migration in
human multiple myeloma cells partly via activation of b1 integrins
[13]. Furthermore, constitutively active b1 integrins promote
malignant phenotype in PrCa cells and targeting them was
reported to inhibit PrCa metastasis [14].
IGF-1 is a single chain polypeptide that in addition to its more
classical endocrine role, mediates autocrine or paracrine growth
and thus acts as a potent growth and survival factor. IGF-1 elicits
its actions on cells by binding to its receptor, IGF-IR. The IGF-IR
is a heterotetrameric transmembrane glycoprotein with tyrosine
kinase activity [15]. The insulin receptor substrate (IRS) proteins
function as specific docking proteins for IGF-IR and insulin
receptor (IR) [16]. IRS1 and IRS2 do not contain intrinsic kinase

Introduction
Adhesion of cells to extracellular matrix (ECM) is primarily
mediated by integrins and is crucial for cell growth and survival.
Integrins are heterodimeric transmembrane receptors, consisting
of a and b subunits, that are non-covalently associated; they
physically link the ECM to the intracellular actin cytoskeleton but
are also able to transduce signals bidirectionally across the plasma
membrane [1]. By binding to ECM ligands, integrins are activated
and able to regulate cellular functions by initiating intracellular
cascades of signaling. So far, 24 integrin heterodimers, 18 a and 8
b subunits and five b1variantsubunits b1Ab1Bb1Cb1C-2 and b1D,
generated by alternative splicing, have been described [2][3].
Integrins are critical regulators of growth, differentiation, survival,
migration and invasion [4,5]. It has been reported that progression
of prostate cancer (PrCa) to advanced stages is associated with
changes in integrin expression profiles [6,7,8].
The pathways of integrin and growth factor signaling are
thought to be mechanistically linked because cell adhesion to
ECM is crucial for cells to respond to certain growth factors [9].
Growth factor signaling can disrupt focal adhesions, the presumed
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and PC3-Ch b1C cells used for inducible expression of chimeric
constructs have been described earlier [25,26]. Cells were serumstarved for 24 h and treated with 75 mM ZnSO4 for 6 h. The Ch1
chimeric construct contains the extracellular domain of murine
CD4 and the transmembrane and cytoplasmic domains of the b1A
integrin; Ch b1C construct (used as a control) is same as Ch1
except that b1A integrin-coding region is replaced by b1C coding
region. Ch2 construct represents another control and carries the
extracellular domain of murine CD4 joined to the transmembrane
domain of the b1 integrin subunit. All the constructs are expressed
under the control of the mouse metallothionein-1 promoter and
the expression of chimeric variants is induced upon addition of
ZnSO4 to the growth medium.

activity but rather function by recruiting proteins to surface
receptors, where they assemble signaling complexes. Signaling
from the IRS proteins results in the activation of pathways
including phosphatidyl inositol-3 kinase (PI3K) and mitogenactivated protein kinase (MAPK) [17,18]. Interestingly, both
pathways are also known to be activated by integrin engagement
[19,20]. The association between integrins and IRS1 has been
suggested as a possible mechanism for synergistic action of growth
factor and extracellular matrix receptors [21]. IGF-1 signaling has
been reported to be regulated by a negative feedback mechanism
via ubiquitin/proteasome mediated degradation of IRS2, whereby
the magnitude and duration of the response to insulin or IGF-1 is
regulated [22]. Our laboratory has recently demonstrated that b1
integrins regulate IGF-IR expression and are critical for IGF-1mediated enhancement of androgen receptor (AR) activity [23].
We have also reported that IGF-IR tightly regulates b1 integrin
expression in PrCa cells [24] but the mechanism underlying this
regulation is not yet characterized.
Despite the limited consensus regarding the levels of IGF-IR
expression in benign and malignant prostate epithelium, several
clinical trials targeting the IGF-IR in different tumors, including
PrCa, are underway. Identifying and understanding the downstream effectors of IGF-IR would help in better defining the
functional role of the IGF-1 axis in PrCa. Given the reported
evidence of strong physical and functional interaction between b1
integrins and IGF-IR, this study investigated the mechanism
through which IGF-IR regulates b1 integrins. We report a novel
pathway of crosstalk between IGF-IR and b1 integrins, which
promotes cancer cell proliferation, and demonstrate that IGF-IR
stabilizes a5b1 integrin by protecting it from proteasomal
degradation.

Transient siRNA transfection
Transient transfection of cells with siRNA oligonucleotides was
performed as described [23]. Inverted-IGF-IR siRNA having an
inverse target sequence of IGF-IR siRNA served as control.

Proliferation assay
LNCaP and C4-2B cells were transiently transfected with
control or IGF-IR siRNA. Twenty four h post-transfection, cells
were trypsinized and analyzed for the efficiency of IGF-IR and b1
integrin downregulation. Transfected cells were counted and replated in triplicates in 6-well plates at 36104 cells per well in 2%
CSS-containing medium in presence of 1 nM R1881. Live cells
were counted for next three consecutive days by haemocytometer.
Pictures of live cells were taken on day 2 and 3 before being
harvested for counting.

Anchorage-independent growth assay
LNCaP cells were plated and transfected with control or IGFIR siRNA in combination with either vector alone, pBJ1, or a pBJ1b1 construct [27]. Twenty four h later, cells were trypsinized and
plated in soft-agar in 6-well dishes at 5,000 cells/well. The cells were
allowed to grow for two weeks and colonies counted. The colony
size was measured by using an eyepiece equipped with a measuring
reticle and colonies with size of 0.1 mm were counted in different
samples. The colonies were fixed and stained with crystal violet and
images of colonies were captured by stereo microscope.

Materials and Methods
Reagents and antibodies
The following reagents were used. Opti-Mem and oligofectamine (all from Invitrogen, CA), synthetic androgen R1881 (PerkinElmer, CA), proteinase inhibitors (Sigma, MO), recombinant
IGF-1 (R&D Systems, MN), MG132 and epoxomicin (Sigma,
MO). The following murine monoclonal antibodies (mAbs) were
used: to b1 integrins (BD Transduction Laboratories, CA), to IGFIR for flow cytometry (aIR-3, EMD, NJ); to a2 integrin (Abcam,
Cambridge, UK); to a7 integrin (8G2, EMD, NJ). Rat mAb to
CD4 was purchased from Santa Cruz, CA. The following rabbit
polyclonal antibodies (pAbs) were used: to IGF-IR (IGF-IR-b
sc713), to AKT and to ERK1/2 (from Santa Cruz, CA); to
survivin (Novus Biologicals, CO). Rabbit pAbs to a3, a4, and a5
specific for the C-terminus domain of each subunit, were a kind
gift from Dr. E. Ruoslahti, University of California Santa Barbara,
Sanford-Burnham Medical Research Institute, CA. The a6 Ab
(AA6A) specific for the C-terminal domain of human a6 integrin
was a kind gift from Dr. Anne Cress, University of Arizona, AZ.
SiRNA oligonucleotides used in this report have been described
before [24].

Immunoprecipitation and Immunoblotting
Immunoprecipitation of PC3 cells was carried out as described
earlier [28]. Cell lysates were used for immunoblotting as
described [12]. To analyze PC3 cell lysates transfected with
chimeric constructs, PC3-Ch1 and PC3-Ch2 cells were transfected
with control or IGF-IR siRNA and 24 h later, cells were grown in
serum-free medium for 24 h followed by treatment with 75 mM
ZnSO4 for 6 h and then, harvested for immunoblotting. The
intensity of each band was evaluated by ImageJ analysis and
normalized with loading control.

FACS analysis
PC3-Ch1 and PC3-Ch2 cells were treated as above and
harvested for FACS analysis. The cells were stained with 1 mg/
ml Ab to CD4 or rat IgG as negative control, followed by staining
with FITC-conjugated secondary Ab. Expression profiles were
acquired using FACS Calibur instrument (BD) and data were
analyzed by Flowjo software (Tree Star Inc., OR).

Cells
LNCaP and C4-2B cells were purchased from ATCC. Cells
were grown at 37uC and 5% CO2 in RPMI-1640 supplemented
with 5% FBS and 1% each of sodium pyruvate, HEPES and nonessential amino acids. To evaluate the effect of agonists, after
transfection cells were starved with 2% charcoal-stripped serum
(CSS) containing medium for 24 h followed by ligand stimulation
for additional 24 h. PC3 cells were grown at 37uC and 5% CO2 in
RPMI-1640 supplemented with 10% FBS. PC3-Ch1, PC3-Ch2
PLOS ONE | www.plosone.org
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LNCaP cells were transfected with control or IGF-IR siRNA
and 24 h later, cells were starved in 2% CSS-containing medium
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for 24 h. Cells were treated with 1 nM R1881 with or without
10 mM MG132 for 6 h. PC3-2 cells were transfected in the same
manner as LNCaP cells and 24 h after transfection treated with
10 mM MG132 for either 6 or 24 h and analyzed by immunoblotting. For specific inhibition of the proteasome function using
epoxomicin, LNCaP cells were transfected as above, starved with
2% CSS-containing medium for 24 h, followed by treatment with
1 nM R1881 together with 0, 100, 250 or 500 nM epoxomicin for
18 h and harvested. Lysates were analyzed by immunoblotting.
Relative band intensities of b1 integrin subunits

Quantitative real time PCR
Real time PCR analysis was performed as described earlier [23].
Each reaction was carried out, at least in triplicate; standard
deviations and significance were calculated using Excel (Microsoft)
software. The sequences of oligos used are as follows: b1 integrin,
(sense: CTCAAGCCAGAGGATATTAC, antisense: TCATTGAGTAAGACAGGTCC), IGF-IR, sense: AATGAGTGCTGCCACCCCGA, antisense: ACACAGCGCCAGCCCTCAAA),
GAPDH, (sense:GGGAAGGTGAAGGTCGGAGT, antisense:
GTTCTCAGCCTTGACGGTGC), b-actin, (sense: TCCAT
CATGAAGTGTGACGT, antisense: GGAGGAGCAATGATCT
TGAT).

Statistical analysis
Statistical significance (P value and t-test) between datasets was
calculated using Excel (Microsoft) software. A two-sided P value of
#0.02 was considered statistically significant. The results were
plotted on a graph using DeltaGraph 4.5 (RockWare) software.

Results
Loss of IGF-IR and b1 integrins inhibits proliferation of
PrCa cells
We have previously demonstrated that b1 integrins are crucial
for IGF-IR-mediated c ancer cell proliferation [10]. Since IGF-IR
tightly regulates b1 integrin expression, we evaluated the direct
effect of IGF-IR depletion on cell proliferation. LNCaP and C42B cells were transiently depleted of IGF-IR and re-plated in 2%
CSS-containing medium in the presence of 1 nM synthetic
androgen (R1881). Loss of IGF-IR strikingly inhibits cell
proliferation in both cell lines (*P,0.02) (Fig. 1A, top panels).
Reduced expression of IGF-IR and b1 integrin subunits for both
cell lines was confirmed by immunoblotting (Fig. 1A, lower
panels). R1881 was used to enhance the expression levels of IGFIR and b1 and to augment the effects of these receptors on
proliferation. Significant effects on cell proliferation were also
observed in the absence of R1881 in LNCaP and C4-2B cells after
IGF-IR depletion (data not shown). Reduced cell density in culture
conditions is clearly observed upon analysis of C4-2B cells with
reduced IGF-IR and b1 levels compared to cells with endogenous
expression of both receptors (Fig. 1B). Representative cell density
images of day 2 and day 3 proliferation assays are shown. These
data show that IGF-IR and b1 integrins are essential for
proliferation of PrCa cells.

Figure 1. Loss of IGF-IR and b1 integrins inhibits proliferation of
PrCa cells. (A) LNCaP and C4-2B cells were transfected with either
control siRNA or IGF-IR siRNA and 24 h later, cells were trypsinized and
counted. Cells were replated in triplicates at 36105 cells per well in 6well plates with 2% CSS-containing medium in the presence of 1 nM
R1881, harvested and counted at day 1, 2 and 3 after re-plating. Each
experimental assay was carried out in triplicates and error bars
represent standard deviation from three independent values
(*P,0.01), relative to respective control siRNA treatments. A parallel
set of LNCaP and C4-2B cell lysates was analyzed for efficiency of IGF-IR
and b1 integrin subunit downregulation by immunoblotting (lower
panels). (B) Representative images of relative C4-2B cell densities on day
2 and day 3 are shown.
doi:10.1371/journal.pone.0076513.g001

integrin expression would reverse the inhibition of anchorageindependent growth induced by IGF-IR depletion, LNCaP cells
were transfected with IGF-IR siRNA, with or without b1 integrin
cDNA, and allowed to grow and form colonies in soft-agar for
two weeks. IGF-IR depletion significantly reduces the growth of
colonies in soft-agar (**P,0.01) (Fig. 2). Exogenous expression of
the b1 subunit however, partially alleviates the growth suppression
induced by IGF-IR knockdown as measured by the number of
colonies with size $100 mm (*P,0.02). Representative images of
live colonies were captured on an inverted microscope and are
shown in the lower panel (Fig. 2). These data underscore the role

Exogenous expression of the b1 integrin subunit restores
the impaired anchorage-independent growth of PrCa
cells upon IGF-IR downregulation
The findings that IGF-IR regulates b1 integrin expression and
that abrogation of IGF- IR compromised the growth of cancer
cells, prompted us to investigate whether b1 integrins play a role in
IGF-IR-mediated growth regulation. In order to determine if b1
PLOS ONE | www.plosone.org
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of b1 integrins in IGF-IR-mediated regulation of growth in PrCa
cells.

IGF-IR regulation of b1 integrin expression does not occur
at the mRNA level
Cooperative effect of these receptors on growth of cancer cells
led us to investigate the mechanism by which IGF-IR regulates b1
expression. We have demonstrated earlier that IGF-IR regulates
the expression of b1 integrin subunits in PrCa cells [24]. This
regulation may occur at the transcriptional, post-transcriptional,
translational or post-translational levels. mRNA regulation of b1
integrins by IGF-IR was analyzed in LNCaP cells by reducing the
expression of IGF-IR by RNA interference, followed by treatment
with R1881 and/or IGF-1. Real time analyses of mRNA
transcripts indicate that IGF-IR mRNA is induced 8-fold upon
R1881 and 2.5-fold upon IGF-1 treatment (Fig. 3). However, no
significant changes in b1 integrin mRNA levels are detected upon
both treatments. Depletion of IGF-IR expression results in fourfold reduction of IGF-IR mRNA after ligand treatments. The data
indicate that b1 integrin transcript levels do not change
significantly upon IGF-IR knockdown. Analysis of GAPDH
expression profile in this experiment served as an additional
reference control. The results clearly indicate that IGF-IR does
not regulate b1 integrin subunits at the mRNA level.

Figure 3. IGF-IR-mediated regulation of b1 integrin expression
does not occur at the mRNA level. LNCaP cells were transfected
with either control or IGF-IR siRNA. Twenty four h later, cells were
grown in medium containing 2% CSS for additional 24 h and treated
with vehicle, 1 nM R1881 or 100 ng/ml IGF-1 for additional 24 h. RNA
isolated from these cells was evaluated for transcript levels of IGF-IR, b1
integrin and GAPDH using quantitative real time PCR. Expression values
were normalized over transcript levels of b-actin and the data are
presented as relative expression. Each reaction was run in triplicate and
error bars represent standard deviation (*P,0.01) relative to untreated
samples.
doi:10.1371/journal.pone.0076513.g003

Inducible expression of CD4-b1A integrin cytoplasmic
domain chimera does not protect the endogenous b1
integrin subunit from degradation induced by IGF-IR
depletion
To explore whether the exogenous expression of the cytoplasmic domain of b1A alters IGF-IR-mediated regulation of
endogenous b1 integrin subunits, chimeric constructs composed
of transmembrane and cytoplasmic domain of b1A integrin with
CD4 extracellular domain (Ch1) were used. The cytoplasmic
domain of the b1 subunit exists in five different spliced forms; the
most widely expressed form in cancer, b1A, regulates b1
localization, cell proliferation and migration [2]. We speculated
that binding of the cytoplasmic domain of b1 integrins to the
IGF-IR would lead to some competition for binding of IGF-IR
to different forms of b1 and result in a b1 protective effect under
depleted IGF-IR conditions. Expression of the Ch1 chimera
(Ch1 cells), or Ch2 chimera, which corresponds to the
transmembrane domain of b1 plus the CD4 extracellular domain
(Ch2 cells), in PC3 cells was induced by ZnSO4 treatment. IGFIR depletion in stably transfected cells was confirmed by
immunoblot analysis (Fig. 4A, top left panel). Induction of the
cytoplasmic b1 variant was confirmed by FACS (Fig. 4A, lower
panels). Upon induction, IGF-IR would be expected to
redistribute and bind to both the endogenous b1 and exogenous
cytoplasmic variant. Exogenous induction of the b1 cytoplasmic
domain, however, does not alter the IGF-IR-mediated regulation
of endogenous b1 integrin levels (Fig 4A, top right panel). In
order to investigate if the b1A cytoplasmic variant physically
interacts with the IGF-IR, immunoprecipitation of CD4 in PC3Ch1 and PC3-Ch b1C cells (stably transfected with cytoplasmic
domain of b1C integrin plus the CD4 extracellular domain [29])
was carried out after incubating the cells with ZnSO4. The

Figure 2. Exogenous expression of b1 integrins rescues the
impaired anchorage-independent growth in absence of IGF-IR.
LNCaP cells were co-transfected with either control or IGF-IR siRNA and
with either the pBJ1-b1 construct or the control vector pBJ1. Cells were
plated in soft-agar and allowed to grow for 2 weeks. The size of the
colonies was measured using an inverted microscope equipped with an
eyepiece containing a 25 mm reticle and total colonies with the size
$100 mm were counted. The numbers shown in the graph represent
the average counts from three independent samples (*P,0.02;
**
P,0.001). Representative images of live colonies reflecting variation
in colony size with or without exogenous b1 are shown in the lower
panels. The measuring bars represent a size of 100 mm.
doi:10.1371/journal.pone.0076513.g002
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by R1881 treatment alone or in combination with a proteasome
inhibitor, MG132, for 6 h. R1881 was used to enhance the basal
expression levels of IGF-IR and b1 integrin subunit as reported by
our group earlier [23] and cell lysates were analyzed. The
reduction of b1 integrin levels induced by IGF-IR depletion was
abolished upon cell treatment with this proteasome inhibitor
(Fig. 5A). The results of this experiment were confirmed in PC3
cells after transfection with either control siRNA or IGF-IR siRNA
followed by treatment with MG132 for either 6 or 24 h (Fig. 5B).
We additionally corroborated these results by using different doses
of epoxomicin, another highly specific proteasome inhibitor [30].
LNCaP cells were transfected with either control or IGF-IR
siRNA as above and treated with increasing concentrations of
epoxomicin. b1 integrin subunits are present in either precursor or

immunoblot shows (upper panel) the presence of IGF-IR in the
cell lysate but not in CD4 immunoprecipitated samples. The
lower panel shows that CD4 was efficiently immunoprecipitated;
an irrelevant band was also detected in the IgG immunoprecipitated samples. The data indicate that the cytoplasmic domain of
the b1A integrin variant does not interact with endogenous IGFIR (Fig. 4B).

Enhanced proteasomal degradation of b1 integrin
subunits in the absence of IGF-IR
After demonstrating that IGF-IR does not regulate b1 integrin
transcripts, we sought to determine whether IGF-IR-mediated
regulation of b1 integrin levels would occur at post-translational
level. Transient depletion of IGF-IR in LNCaP cells was followed

Figure 4. Exogenous CD4 - b1 integrin cytoplasmic domain chimera does not influence the IGF-IR-mediated regulation of the
endogenous b1. (A) PC3-Ch1 (expressing extracellular domain of murine CD4 and the transmembrane and cytoplasmic domains of b1) and control
PC3-Ch2 cells (expressing the extracellular domain of murine CD4 joined to the transmembrane domain of the b1) were transfected with either
control or IGF-IR siRNA. Twenty-four h post transfection, cells were harvested to evaluate the efficiency of IGF-IR knockdown (top left panels). PC3Ch1 and PC3-Ch2 cells were starved in serum-free medium for 24 h and where indicated, induced with 75 mM ZnSO4 for additional 6 h to promote
the expression of chimeric proteins. Cells were harvested for analysis of b1 subunit expression (top right panels). A parallel set of samples was
processed to confirm the inducible expression of the chimeras by FACS analysis using an Ab to CD4 (lower panels). 10,000 cells in each sample were
acquired and data are shown in histograms with the x-axis representing mean relative CD4 expression and the y-axis representing the number of
cells. (B) PC3-Ch1 and PC3-Chb1C (control cells expressing extracellular domain of murine CD4 and the transmembrane and cytoplasmic domains of
the b1C) incubated with 75 mM ZnSO4 to induce the expression of the cytoplasmic domain of b1A or b1C integrins, respectively. Lysates were
immunoprecipitated with either control IgG or Ab against chimeric CD4 domains. Immunocomplexes were analyzed for IGF-IR expression by
immunoblotting. Input lysates were run as controls.
doi:10.1371/journal.pone.0076513.g004

PLOS ONE | www.plosone.org

5

October 2013 | Volume 8 | Issue 10 | e76513

b1 Integrin Regulation by IGF-IR

inhibitory, as described for TNF receptor-1, effect of the crosstalk
between growth factor receptors and cell-surface integrins is an
area which has attracted much interest in recent years
[38,39,40,41]. The crosstalk appears to be mediated by a direct
interaction between growth factor receptors and cell-surface
integrins; we have previously demonstrated that b1 integrins
physically associate with the IGF-IR [12]. In an effort to further
characterize this interaction, we exogenously induced a chimeric
protein containing the cytoplasmic domain of the b1 integrin
subunit to test if it binds IGF-IR. We do not, however, observe any
association of the chimeric cytoplasmic domain of b1 integrins
with IGF-IR; thus, further analysis is necessary to identify the
domains that mediate this interaction. It should be stressed that
IGF-1 has been reported to directly bind to integrins and induce
the formation of a ternary complex containing integrin-IGF1-IGFIR [42,43]. The authors report that an integrin-binding-defective
mutant of IGF-1 (R36E/R37E IGF-1), which still binds IGF-IR,
acts as a dominant-negative antagonist of IGF-IR and suppresses
tumorigenesis; they also show that IGF-1 binds to a6b4 as well as
to b1 integrins, consistent with our data.
IGF-IR regulation of b1 integrin expression, is critical in the
context of reported alterations in the IGF-1 axis signaling and
expression during cancer progression [44], and implies that
variations of the levels of one receptor may influence the profile
of other receptors. Consistent with this, we have reported
concurrent upregulation of b1 integrins and IGF-IR in prostatic
intraepithelial neoplasia and well differentiated prostate carcinoma [10]. We now demonstrate that in the absence of IGF-IR, b1
integrins are subjected to proteasome-mediated degradation
suggesting that the interaction between IGF-IR and b1 integrins
not only provides synergistic signaling but enhances the stability
of both proteins. b1 loss by proteasomal degradation has been
previously reported in Talin-1 null embryonic stem cells leading
to defective integrin-adhesion complex assembly. Since Talin-1
overexpression has been reported to enhance PrCa invasion and
disrupting Talin-1 signaling/focal adhesion interactions was
proposed to have a therapeutic significance in targeting
metastatic PrCa [45,46], we speculate that the IGF-IR/b1
integrin pathway may be altered in the absence of Talin-1.
IGF-IR mutants with impaired PI3K-AKT signaling were
reported to exhibit receptor ubiquitination and were degraded
by proteasomes. However, C-terminal truncated IGF-IR failed to
undergo ubiquitination and was exclusively degraded through
lysosomal pathways [47]. Moreover, our experiments suggesting
proteasomal degradation of b1 upon IGF-IR depletion do not
exclude the possibility that b1 integrins may also be in part
processed through lysosomal or recycled through endosomal
pathways. Similar to what is known of the ligand-induced
ubiquitination of growth factor receptors, a5b1 was recently
reported to be ubiquitinated followed by degradation in response
to fibronectin binding [48]. Our results suggest that in the
absence of IGF-IR, b1 integrins are ubiquitinated and marked
for proteasomal and/or lysosomal degradation. A Sorting Nexin
family protein, SNX17 was recently reported to regulate the
stability of b1 and it would be crucial to determine if SNX17 is
involved in IGF-IR-mediated regulation of b1 integrins [49,50].
Furthermore, it is equally important to investigate if b1-integrin
degradation triggered by IGF-IR loss involves clathrin- or
caveolin-dependent endocytosis. It could be speculated that
recycling of b1 from early endosomes back to cell membrane can
occur through a rapid recycling route by returning to the cell
surface directly from endosomes or through a slow recycling
route involving Rab GTPases such as Rab4 and Rab11 [28,51].

mature forms (110 and 130 kD respectively) and both are
downregulated upon IGF-IR loss. The data show that epoxomicin
blocks the degradation of the mature form of the b1 integrin
subunit (Fig. 5C). The mature b1 receptor alone appears to follow
proteasomal degradation after internalization. The precursor form
of b1 (110 kD) which needs further post-translational modifications
to undergo maturation is not recovered by proteasomal inhibition.
The data show that IGF-IR stabilizes b1 integrin subunit
expression by inhibiting its proteasomal degradation.

Analysis of a integrin subunits upon IGF-IR
downregulation
Integrins are heterodimers consisting of a and b subunits. There
are 24 possible heterodimers with the ability to activate specific
signaling pathways [19]. b1 integrins, among other subunits, are
known to heterodimerize with a2, a3, a4, a5, a6 and a7 integrin
subunits, which are expressed in LNCaP cells. Since reduction of
IGF-IR expression levels leads to the downregulation of the b1
integrin subunit, we decided to determine which a integrin subunit
was affected by IGF-IR downregulation. We demonstrate a
significant reduction of the a5 integrin subunit in conjunction with
reduced IGF-IR and b1 levels (Fig. 6). No change was detected in
the expression levels of other a integrin heterodimeric partners
(Fig. 6 and data not shown). These results are consistent with our
previous observations in PC3 cells where abrogation of b1
integrins by shRNA led to a significant reduction in the surface
expression of a5 integrin subunit [3]. Our data demonstrate that
the major complex regulated by IGF-IR is a5b1 integrin.

Discussion
This study describes a novel observation that IGF-IR functions
in PrCa cells are partially mediated by b1 integrins. To dissect the
mechanism by which IGF-IR regulates b1 integrin expression, we
demonstrate that IGF-IR enhances b1 integrin stability by
reducing its proteasomal degradation. We also show that the a5
integrin subunit associated with b1 is selectively downregulated
upon IGF-IR loss.
Substantial epidemiological and preclinical data have identified
the IGF-IR pathway as an important regulator of tumor cell
biology. The disappointing results, however, from several clinical
trials aimed to inhibit IGF-IR, are prompting researchers to
develop predictive biomarkers to improve patient selection that
would benefit from therapies targeting IGF-IR. Moreover, a
clearer understanding of relative proportions of IGF-IR and IR
complexes in tumors is necessary. In this regard, tyrosine kinase
inhibitors specific for both the IGF-IR and IR could address the
concern that increased IR signaling occurs upon IGF-IR
inhibition [31]. Interestingly, a combination of IGF-IR and
MEK inhibitors was recently reported to result in significant
inhibition of K-Ras-mutant lung cancer lines and also improve
effectiveness in two mouse models of K-Ras-driven lung cancer
[32]. Understanding the functional crosstalk of IGF-IR with
integrins will potentially open up novel approaches to block this
crucial signaling pathway. Our demonstration of the critical role
played by IGF-IR and b1 in regulating biological responses of
PrCa cells, both in anchorage-dependent and -independent
growth, is in agreement with previous findings that integrins are
crucial for IGF-IR-mediated mitogenic and transforming activities
[10,33,34,35]. Similar crosstalk has been observed between IGFIR and E-cadherin, a complex shown to mediate cell-cell adhesion
in human breast cancer cells [36], and among IGF-IR, E-cadherin
and aV integrins, shown to have dynamic interactions under the
control of a catenin [37]. The stimulatory, as described here, or
PLOS ONE | www.plosone.org
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Figure 5. Loss of IGF-IR causes proteasome-mediated degradation of b1 integrins. (A) LNCaP cells were transfected with either control or
IGF-IR siRNA. Twenty four h later, cells were grown in medium containing 2% CSS for additional 24 h and treated with vehicle, 1 nM R1881 and/or
10 mM MG132 for 6 h. Cell lysates were analyzed for expression of b1 integrin subunit and IGF-IR by immunoblotting. AKT was used as a loading
control. The band intensities of the b1 integrin subunit were quantitated by ImageJ analysis and normalized with those of AKT as a loading control.
The relative intensity values are expressed as percent of the control sample transfected with control siRNA alone. (B) PC3 cells were transfected with
either control or IGF-IR siRNA. Twenty four h after transfection, cells were treated with 10 mM MG132 for 6 or 24 h in RPMI medium containing 10%
serum. Cell lysates were analyzed for expression of b1 integrin subunit and IGF-IR by immunoblotting. AKT was used as a loading control. b1 integrin
subunits were quantitated by ImageJ as above and values normalized with those of loading control AKT. Relative intensity values of b1 are expressed
as percent of the control sample transfected with control siRNA alone. (C) LNCaP cells were transfected as above and 24 h later cells were cultured in
medium containing 2% CSS for additional 24 h followed by treatment with 0, 100, 250 or 500 nM epoxomicin in combination with 1 nM R1881 for
18 h. Cell lysates were analyzed for mature and precursor forms of b1 integrin subunit and IGF-IR by immunoblotting. AKT serves as a loading control.
Relative band intensities of mature b1 integrin were determined by ImageJ analysis as above.
doi:10.1371/journal.pone.0076513.g005

IGF-IR might be involved in regulating the immature form of b1
integrins.
Downregulation of the b1 integrin subunit has been shown to
significantly reduce the surface expression of the associated a5
subunit in PrCa cell lines [3]. Our novel finding that a5 integrin
subunit is significantly reduced upon IGF-IR downregulation, is
consistent with direct causal role of IGF-IR on b1 expression, as
we previously reported [24]. Consistent with this, other laboratories have recently shown that in vivo inhibition of a5 integrin
significantly reduces tumor growth [52]. These findings support a

Our data show that proteasomal inhibition rescues the
degradation of the b1 integrin subunit upon IGF-IR downregulation. Although we have observed the downregulation of both
mature (130 kD) and precursor (110 kD) forms of b1 integrins
upon IGF-IR knockdown, only the mature b1 form is recognized
by the proteasomal machinery and thus preferentially degraded. It
is, however, not clear how IGF-IR regulates the immature form of
b1 integrins. Since we did not observe any changes in mRNA
levels upon ablation of IGF-IR, other effectors downstream of
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detachment and apoptosis was reported to be caused by Cbldependent ubiquitination of a5 integrin [55]. Endosomal accumulation of integrins is prevented by ligand-mediated degradation
of the a5b1 integrin, which might otherwise develop nonproductive adhesion sites. Fibroblast migration was reported to
be regulated by trafficking of fibronectin and ubiquitinated a5b1
complexes to lysosomes for degradation [48]. It could be
speculated that upon loss of IGF-IR, a5b1 integrin is shuttled to
proteasomes and lysosomes for degradation instead of being
translocated to early endosomes for recycling.
In conclusion, this paper highlights a novel pathway mediated
by IGF-IR and a5b1 integrin in PrCa growth and dissects the
mechanism by which IGF-IR regulates the expression of a5b1
integrin. We propose that IGF-IR signaling, by controlling the
stability of the a5b1 integrin through a proteasomal pathway,
tightly regulates pro-survival signaling in PrCa.

Figure 6. b1 integrin downregulation upon IGF-IR depletion is
associated with reduced a5 integrin subunit expression. LNCaP
cells were transfected with either control or IGF-IR siRNA and treated
with 2% CSS-containing medium for 24 h followed by treatment with
1 nM R1881 for 24 h. IGF-IR and b1 integrin downregulation was
evaluated by immunoblots. The lysates were then analyzed for the
expression of various a integrin subunits. Specific Abs against a2, a4, a5,
a6 and a7 integrin subunits were used to identify the a integrin partner
of the b1 integrin subunit, which is downregulated upon IGF-IR
depletion.
doi:10.1371/journal.pone.0076513.g006
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